<unk>  is a combination of a neprilysin inhibitor and an angiotensin II receptor blocker that is FDA approved for the prevention of of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include hypotension, increased serum potassium, hyperkalemia, and increased serum creatinine.
Sacubitril and Valsartan
Amlodipine and Benazepril
Amlodipine besylate and Valsartan
Losartan potassium and Hydrochlorothiazide
Lisinopril and Hydrochlorothiazide
Amlodipine besylate and Olmesartan medoxomil
Spironolactone and hydrochlorothiazide
Captopril and Hydrochlorothiazide